查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肺動脈高壓市場、份額、規模、趨勢、產業分析報告：按類型、藥物類別、給藥途徑、地區、細分市場預測，2023-2032 年
市場調查報告書
商品編碼
1421703

肺動脈高壓市場、份額、規模、趨勢、產業分析報告：按類型、藥物類別、給藥途徑、地區、細分市場預測，2023-2032 年

Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 115 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，到 2032 年，全球肺動脈高壓市場規模預計將達到 113.5 億美元。 該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

由於老年人口越來越容易受到此類健康狀況的影響，心血管疾病和肺部疾病的盛行率不斷增加，預計將在未來幾年推動肺動脈高壓(PAH) 市場的發展。預計將推動肺動脈高壓(PAH) 市場的擴張。 此外，過度飲酒、久坐、不健康飲食等不良生活習慣也會增加高血壓、高血脂的風險。 再加上新的孤兒藥和技術先進的肺動脈高壓治療設備的推出、公眾對肺動脈高壓可用治療方案的認識的提高以及醫療基礎設施的改善，預計將刺激肺動脈高壓的進一步增長高血壓（PAH）市場。 然而，嚴格的藥品監管對未來市場成長構成挑戰。

PAH 的症狀各不相同，包括氣短、疲勞、胸痛、頭暈、昏厥以及腳、腿或胃腫脹。 這些症狀隨著時間的推移而進展，並對個人的生活品質產生重大影響。 PAH 是一種進行性疾病，可導致右心衰竭、心律不整和肺血栓形成等併發症，嚴重時可導致死亡。 因此，早期診斷和治療對於有效控制疾病起著關鍵作用。 由肺科醫生、心臟科醫生和其他專家組成的專業醫療團隊的定期監測對於 PAH 患者至關重要。 他們可以監督您的醫療狀況，進行必要的藥物調整，並提供重要的支援。 此外，也建議改變生活方式，例如定期運動、保持均衡飲食、避免吸煙和避免呼吸道刺激，以促進有效的疾病管理。

此外，國家醫學圖書館 2021 年 6 月發表的一項研究強調了冠狀動脈疾病 (CAD) 對全球健康的重大影響。 光是 CAD 每年就導致約 61 萬人死亡，佔估計死亡人數的四分之一，是美國的第一大死因。 隨著 CAD 發病率的增加，對有效的肺動脈高壓治療設備的需求不斷增長，以滿足這一緊迫的醫療需求。 因此，預計該因素將在預測期內推動對肺動脈高壓的需求。

肺動脈高壓市場報告亮點

2022 年，由於強勁的需求和不斷擴大的應用，前列環素和前列環素類似物領域佔據了市場上最大的收入份額。 此外，SGC 刺激器領域預計成長最快，複合年增長率超過 5%。 SGC 刺激劑有望增強 NO-sGC 訊號傳導並最大化 sGC 活化。

在預測期內，口服藥物細分市場佔據主導地位，這主要是由於治療肺動脈高壓的口服製劑的供應不斷增加以及患者對口服給藥的偏好。 口服 PAH 治療的著名例子包括 Letairis、Adcirca、Opsumit 和 Revatio。

2022年，北美引領全球市場，主要得益於美國和加拿大成熟的醫療基礎設施，有利於獲得先進的治療。 此外，意識的提高、高診斷率和政府支持措施也促進了該地區的市場成長。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第 4 章全球肺動脈高壓市場洞察

  • 肺動脈高壓市場－給藥途徑概覽
  • 肺動脈高壓市場動態
    • 推動者和機會
      • 肺動脈高壓 (PAH) 病例推動市場成長
      • 可溶性鳥甘酸環化□ (SGC) 刺激劑的進展
    • 抑制因素和挑戰
      • 重要專利到期
  • PESTEL 分析
  • 肺動脈高壓市場的給藥途徑趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第 5 章全球肺動脈高壓市場（依藥物類別）

  • 主要發現
  • 簡介
  • PDE-5抑制劑
  • 前列環素和前列環素類似物
  • SGC 刺激器
  • 內皮素受體拮抗劑（ERA）

第 6 章全球肺動脈高壓市場（按類型）

  • 主要發現
  • 簡介
  • 通用
  • 品牌

第 7 章全球肺動脈高血壓市場（依給藥途徑）

  • 主要發現
  • 簡介
  • 靜脈/皮下
  • 用於吸入
  • 口頭

第 8 章按地區劃分的全球肺動脈高壓市場

  • 主要發現
  • 簡介
    • 肺動脈高壓市場評估，地區，2019-2032
  • 肺動脈高壓市場 - 北美
    • 北美：肺動脈高壓市場，依藥物類別，2019-2032 年
    • 北美：2019-2032 年肺動脈高壓市場（依給藥途徑）
    • 北美：肺動脈高壓市場，依類型，2019-2032 年
    • 肺動脈高壓市場 - 美國
    • 肺動脈高壓市場 - 加拿大
  • 肺動脈高壓市場 - 歐洲
    • 歐洲：肺動脈高壓市場，依藥物類別，2019-2032 年
    • 歐洲：2019-2032 年肺動脈高壓市場（依給藥途徑）
    • 歐洲：2019-2032 年肺動脈高壓市場（按類型）
    • 肺動脈高壓市場 - 英國
    • 肺動脈高壓市場 - 法國
    • 肺動脈高壓市場 - 德國
    • 肺動脈高壓市場 - 義大利
    • 肺動脈高壓市場 - 西班牙
    • 肺動脈高壓市場 - 荷蘭
    • 肺動脈高壓市場 - 俄羅斯
  • 肺動脈高壓市場 - 亞太地區
    • 亞太地區：肺動脈高壓市場，依藥物類別，2019-2032 年
    • 亞太地區：2019-2032 年肺動脈高壓市場（依給藥途徑）
    • 亞太地區：肺動脈高壓市場，依類型，2019-2032 年
    • 肺動脈高壓市場 - 中國
    • 肺動脈高壓市場 - 印度
    • 肺動脈高壓市場 - 馬來西亞
    • 肺動脈高壓市場 - 日本
    • 肺動脈高壓市場 - 印尼
    • 肺動脈高壓市場 - 韓國
  • 肺動脈高壓市場 - 中東和非洲
    • 中東和非洲：2019-2032 年肺動脈高壓市場（依藥物類別）
    • 中東和非洲：2019-2032 年肺動脈高壓市場（依給藥途徑）
    • 中東和非洲：2019-2032 年肺動脈高壓市場（按類型）
    • 肺動脈高壓市場 - 沙烏地阿拉伯
    • 肺動脈高壓市場 - 阿拉伯聯合大公國
    • 肺動脈高壓市場 - 以色列
    • 肺動脈高壓市場 - 南非
  • 肺動脈高壓市場 - 拉丁美洲
    • 拉丁美洲：肺動脈高壓市場，依藥物類別，2019-2032 年
    • 拉丁美洲：2019-2032 年肺動脈高壓市場（依給藥途徑）
    • 拉丁美洲：肺動脈高壓市場，按類型，2019-2032 年
    • 肺動脈高壓市場 - 墨西哥
    • 肺動脈高壓市場 - 巴西
    • 肺動脈高壓市場 - 阿根廷

第九章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 夥伴關係/協作/協議/揭露

第十章公司簡介

  • Bayer
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Sandoz Inc.（Novartis）
  • Sun Pharmaceutical Industries, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corporation
  • Viatris Inc.
Product Code: PM4051

The global pulmonary arterial hypertension market size is expected to reach USD 11.35 billion by 2032, according to a new study by Polaris Market Research. The report "Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of cardiovascular and pulmonary disorders, driven by a growing elderly population susceptible to such health conditions, is poised to drive the pulmonary arterial hypertension (PAH) market's expansion in the forthcoming years. Moreover, lifestyle modifications, such as excessive alcohol consumption, sedentary behavior, and unhealthy dietary habits, have heightened the risk of hypertension and high blood pressure. This, combined with the introduction of novel orphan drugs and technologically advanced treatment devices for pulmonary arterial hypertension (PAH), increased awareness among the public regarding available treatment options for PAH, and improved healthcare infrastructure, is expected to fuel further the growth of the pulmonary arterial hypertension (PAH) market. However, stringent drug regulations pose a challenge to the market's growth in the years ahead.

Symptoms of PAH can exhibit variability and may encompass shortness of breath, fatigue, chest pain, dizziness, fainting, and swelling in the feet, legs, and stomach. Over time, these symptoms can progress, significantly impacting an individual's quality of life. PAH is a progressive ailment that may lead to complications, including right-sided heart failure, arrhythmias, lung blood clots, and, in severe instances, mortality. Therefore, early diagnosis and treatment play a vital role in effectively managing the condition. Regular monitoring by a specialized healthcare team comprising pulmonologists, cardiologists, and other experts is essential for individuals with PAH. They can oversee the condition, make necessary medication adjustments, and provide vital support. Furthermore, lifestyle changes like regular exercise, maintaining a balanced diet, and avoiding smoking and respiratory irritants may be advised to facilitate effective condition management.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Pulmonary Arterial Hypertension devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Pulmonary Arterial Hypertensions throughout the forecast period.

Pulmonary Arterial Hypertension Market Report Highlights

In 2022, the Prostacyclin and Prostacyclin Analogs segment claimed the largest share of revenue in the market, attributed to robust demand and expanding applications. Additionally, the SGC stimulators segment is expected to exhibit the swiftest growth, featuring a CAGR surpassing 5%. SGC stimulators hold promise for enhancing NO-sGC signaling and maximizing sGC activation.

During the forecast period, the Oral segment dominated the market, primarily due to the growing availability of oral formulations for pulmonary arterial hypertension and patient preference for oral administration. Notable examples of oral PAH drugs comprise Letairis, Adcirca, Opsumit, and Revatio.

In 2022, North America led the global market, primarily driven by its well-established healthcare infrastructure in the United States and Canada, facilitating advanced therapeutic access. Moreover, increased awareness, a high diagnosis rate, and government support initiatives contribute to the market's growth in this region.

The global key market players include: Bayer, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Viatris Inc.

Polaris Market Research has segmented the Pulmonary Arterial Hypertension market report based on type, drug class, route of administration, and region:

Pulmonary Arterial Hypertension, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Generics
  • Branded

Pulmonary Arterial Hypertension, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • PDE-5 Inhibitors
  • Prostacyclin and Prostacyclin Analogs
  • SGC Stimulators
  • Endothelin Receptor Antagonists (ERAs)

Pulmonary Arterial Hypertension, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Intravenous/ subcutaneous
  • Inhalational
  • Oral

Pulmonary Arterial Hypertension, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pulmonary Arterial Hypertension Market Insights

  • 4.1. Pulmonary Arterial Hypertension Market - Route of Administration Snapshot
  • 4.2. Pulmonary Arterial Hypertension Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Cases of Pulmonary Arterial Hypertension (PAH) Facilitate Market Growth
      • 4.2.1.2. Advancement of soluble guanylate cyclase (SGC)-stimulating drugs
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Expiration of critical patents
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Pulmonary Arterial Hypertension Market Route of Administration Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pulmonary Arterial Hypertension Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. PDE-5 Inhibitors
    • 5.3.1. Global Pulmonary Arterial Hypertension Market, by PDE-5 Inhibitors, by Region, 2019-2032 (USD Billion)
  • 5.4. Prostacyclin and Prostacyclin Analogs
    • 5.4.1. Global Pulmonary Arterial Hypertension Market, by Prostacyclin and Prostacyclin Analogs, by Region, 2019-2032 (USD Billion)
  • 5.5. SGC Stimulators
    • 5.5.1. Global Pulmonary Arterial Hypertension Market, by SGC Stimulators, by Region, 2019-2032 (USD Billion)
  • 5.6. Endothelin Receptor Antagonists (ERAs)
    • 5.6.1. Global Pulmonary Arterial Hypertension Market, by Endothelin Receptor Antagonists (ERAs), by Region, 2019-2032 (USD Billion)

6. Global Pulmonary Arterial Hypertension Market, by Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 6.3. Generics
    • 6.3.1. Global Pulmonary Arterial Hypertension Market, by Generics, by Region, 2019-2032 (USD Billion)
  • 6.4. Branded
    • 6.4.1. Global Pulmonary Arterial Hypertension Market, by Branded, by Region, 2019-2032 (USD Billion)

7. Global Pulmonary Arterial Hypertension Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • 7.3. Intravenous/ subcutaneous
    • 7.3.1. Global Pulmonary Arterial Hypertension Market, by Intravenous/ subcutaneous, By Region, 2019-2032 (USD Billion)
  • 7.4. Inhalational
    • 7.4.1. Global Pulmonary Arterial Hypertension Market, by Inhalational, By Region, 2019-2032 (USD Billion)
  • 7.5. Oral
    • 7.5.1. Global Pulmonary Arterial Hypertension Market, by Oral, By Region, 2019-2032 (USD Billion)

8. Global Pulmonary Arterial Hypertension Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Pulmonary Arterial Hypertension Market - North America
    • 8.3.1. North America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.2. North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.3.3. North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.3.4. Pulmonary Arterial Hypertension Market - U.S.
      • 8.3.4.1. U.S.: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.3.5. Pulmonary Arterial Hypertension Market - Canada
      • 8.3.5.1. Canada: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4. Pulmonary Arterial Hypertension Market - Europe
    • 8.4.1. Europe: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.4. Pulmonary Arterial Hypertension Market - UK
      • 8.4.4.1. UK: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.5. Pulmonary Arterial Hypertension Market - France
      • 8.4.5.1. France: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.6. Pulmonary Arterial Hypertension Market - Germany
      • 8.4.6.1. Germany: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.7. Pulmonary Arterial Hypertension Market - Italy
      • 8.4.7.1. Italy: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.8. Pulmonary Arterial Hypertension Market - Spain
      • 8.4.8.1. Spain: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.9. Pulmonary Arterial Hypertension Market - Netherlands
      • 8.4.9.1. Netherlands: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.10. Pulmonary Arterial Hypertension Market - Russia
      • 8.4.10.1. Russia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.5. Pulmonary Arterial Hypertension Market - Asia Pacific
    • 8.5.1. Asia Pacific: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.4. Pulmonary Arterial Hypertension Market - China
      • 8.5.4.1. China: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.5. Pulmonary Arterial Hypertension Market - India
      • 8.5.5.1. India: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.6. Pulmonary Arterial Hypertension Market - Malaysia
      • 8.5.6.1. Malaysia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.7. Pulmonary Arterial Hypertension Market - Japan
      • 8.5.7.1. Japan: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.8. Pulmonary Arterial Hypertension Market - Indonesia
      • 8.5.8.1. Indonesia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.9. Pulmonary Arterial Hypertension Market - South Korea
      • 8.5.9.1. South Korea: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.6. Pulmonary Arterial Hypertension Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.4. Pulmonary Arterial Hypertension Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.5. Pulmonary Arterial Hypertension Market - UAE
      • 8.6.5.1. UAE: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.6. Pulmonary Arterial Hypertension Market - Israel
      • 8.6.6.1. Israel: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.7. Pulmonary Arterial Hypertension Market - South Africa
      • 8.6.7.1. South Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.7. Pulmonary Arterial Hypertension Market - Latin America
    • 8.7.1. Latin America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.7.4. Pulmonary Arterial Hypertension Market - Mexico
      • 8.7.4.1. Mexico: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.7.5. Pulmonary Arterial Hypertension Market - Brazil
      • 8.7.5.1. Brazil: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.7.6. Pulmonary Arterial Hypertension Market - Argentina
      • 8.7.6.1. Argentina: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Bayer
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Gilead Sciences, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. GlaxoSmithKline
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Johnson & Johnson
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Lupin Pharmaceuticals, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sandoz Inc. (Novartis)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Sun Pharmaceutical Industries, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Teva Pharmaceutical Industries Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. United Therapeutics Corporation
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Viatris Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 3 Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 4 Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 7 North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 8 U.S.: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 U.S.: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 11 Canada: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 14 Europe: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 17 UK: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 19 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 20 France: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 22 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 23 Germany: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 26 Italy: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 29 Spain: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 35 Russia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Russia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 41 China: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 China: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 43 China: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 44 India: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 India: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 46 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 50 Japan: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 56 South Korea: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 65 UAE: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 66 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 68 Israel: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Israel: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 71 South Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 72 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 74 Latin America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 Latin America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 77 Mexico: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 78 Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 80 Brazil: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 83 Argentina: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 84 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Pulmonary Arterial Hypertension Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Pulmonary Arterial Hypertension Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Pulmonary Arterial Hypertension Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Route of Administration
  • Figure 11. Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2022 & 2032 (USD Billion)
  • Figure 12. Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Pulmonary Arterial Hypertension Market